CD274 and hepatocellular carcinoma: Subsequently, the combination of PD-L1 inhibitor (Atelizumab) and Bevacizumab (“T+A” scheme for short) in the phase III clinical trial (IMbrave150) for the treatment of advanced hepatocellular carcinoma significantly improved the survival period and quality of life of patients (4, 70, 71).